

PRESS RELEASE - FOR IMMEDIATE RELEASE

## IntegraGen - 2010 Financial Results

**Double-digit growth in genomic services, establishment of a new oncology franchise, market launch and ongoing development of autism panel tests on schedule.**

- Genomic services: €3.2 million in turnover (a 14% year-on-year increase)
- Autism: market launch of the ARISK™ Familial Autism test in the United States
- Oncology: implementation of biomarker validation programs
- Net cash position as of December 31, 2010: €6 million

**EVRY (FRANCE), FRIDAY, APRIL 8, 2011** - The French molecular diagnostics company **IntegraGen** today announced its financial results for 2010. The 2010 accounts were reviewed during the Board meeting on April 7, 2011.

<b>KEY FIGURES</b> (in thousands of euros)	<b>2010</b>	<b>2009</b>
Turnover	<b>3208</b>	2813
Operating profit/loss	<b>-2808</b>	- 2837
Net profit/loss	<b>-2896</b>	- 2734
Cash position as of December 31 2010	<b>6018</b>	1429

**Chairman and CEO Bernard Courtieu** commented:

*"The financial results for 2010 confirm our market leadership for genomic services in France. In 2010 we also maintained the dynamic trend of our molecular diagnostics business; In fact, IntegraGen has confirmed its ability to take its proprietary assays through to market; our North American partner Transgenomic has validated our ARISK™ Familial Autism Panel and integrated it into its product portfolio and in turn make it available to Clinicians since the summer of 2010".*

NB: audit procedures have been run on the accounts. The certified accounts will be issued after verification of the management report and finalization of the procedures required for publication of the annual financial statement.

## **BUSINESS ACTIVITY**

- **Genomic Services: sustained growth, driven by very-high-throughput sequencing**

With a 2010 turnover of €3.2 million (a 14% increase on 2009), IntegraGen has confirmed its position as the benchmark supplier of genomic services to the French market.

This revenue stream comes from three different activities: medium- and high-throughput genotyping (accounting for 10% and 65%, respectively) and very-high-throughput sequencing (25%). The latter service accounted for most of 2010's turnover growth because it represented only 4% of sales in 2009.

During the 2010 fiscal year, IntegraGen ran over 70 projects for more than 50 different customers, including the French National Institute for Health and Medical Research (INSERM), the French League against Cancer charity, Sanofi-Aventis and Servier.

- **Autism: market launch of the ARISK™ test and development of scientific and clinical collaborations in the United States**

Autism is a developmental disorder that affects one child in 150 and manifests itself by a triad of symptoms (socialization, communication and behavior disorders). Early diagnosis as a prelude to early treatment is now considered to be decisive in the management of patients with autism.

In the United States, our commercial partner Transgenomic launched the ARISK™ Familial Autism Panel in June 2010. The ARISK test helps evaluate the risk of autism in children who have a sibling affected by this condition. The test's availability in the US market is now enabling IntegraGen to forge and reinforce scientific and (above all) clinical collaborations with key players and accurately target the main specialist centers.

Furthermore, prospective clinical studies of the non-familial version of the panel are being planned with top-class North American investigating centers and the protocols will be initiated in 2011.

Lastly, IntegraGen has signed a joint ownership and exclusive licensing agreement with Johns Hopkins University and Massachusetts General Hospital concerning the diagnostic use of a biomarker related to the JARID 2 gene. IntegraGen is thus sharpening its pioneering position as a leader in the search for gene variants that may constitute a genetic signature for the risk of autism.

- **Oncology**

In late 2010, IntegraGen started to collaborate with a number of INSERM research units on the validation of diagnostic biomarkers in the field of hepatocellular carcinoma and metastatic colorectal cancer. These developments are intended to broaden the company's range of products and create tools for the personalized management of patients suffering from these tumors.

The projects' initial results have confirmed the robustness and pharmacogenetic and clinical value of the biomarkers under consideration.

## FINANCIALS

### ▪ Income statement

**Turnover** for the 2010 fiscal year amounted to €3.2 million (versus €2.8 million in 2009, i.e. a 14% rise). This growth was linked to development of the company's genomic services in general and very-high-throughput sequencing in particular - a complex technology for which IntegraGen is the French market leader.

The **operating loss** for 2010 was €2.8 million - a similar figure to the previous year.

Consumables costs rose in proportion to the increase in business activity.

Expenditure on external services remained under firm control.

Payroll costs amounted to €1.84 million in 2010 (versus €1.66 million in 2009), reflecting the growth in staff numbers and the acquisition of new skills in R&D and clinical genetics.

R&D expenditure for 2010 was stable, at €1.4 million. It mainly concerned the development of future versions of the ARISK™ autism panel and, secondly, initiation of the company's oncology program.

The **financial loss** for 2010 was €0.2 million, versus €0.6 million in 2009. This mainly comprised depreciation expenses and provisions.

The **profit/loss including exceptional items** for 2010 was negative, with a €0.5 million loss due to an exceptional €0.46 million charge (IPO fees).

The **net loss** was €2.9 million in 2010, which compares with a loss of €2.7 million for the 2009 fiscal year.

### ▪ Balance sheet

As of December 31, 2010, IntegraGen's balance sheet had been reinforced by a €6.7 million private placement performed prior to the company's IPO in June 2010.

Accordingly, IntegraGen's **net cash and cash equivalents** at the end of the 2010 fiscal year stood at €6 million, versus €1.4 million as of December 31, 2009.

## THE OUTLOOK FOR 2011

In 2011, IntegraGen expects to pursue the validation of its diagnostic tests, with a particular focus on a 2012 market launch of a non-familial version of the ARISK™ autism panel. This validation will mainly be based on a prospective clinical study conducted with some leading US academic centers and is due to start this year.

The company will continue to provide scientific and clinical support in promoting its tests for familial and non-familial genetic predispositions.

The company intends to continue to post double-digit growth in its genomic services business, fueled by strong demand from private and public R&D organizations for cutting-edge techniques that are essential for today's pharmacogenomics projects.

IntegraGen confirms its goal of profitability by 2013.

## **ABOUT INTEGRAGEN**

IntegraGen (based in Evry, France) is a biotechnology company dedicated to gene discovery. Its goal is to develop molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment and therapy. IntegraGen and its wholly owned U.S. subsidiary IntegraGen, Inc., are focused on the prevention and proactive management of complex, debilitating diseases and dedicated to addressing the needs of patients, clinicians and advocacy groups. IntegraGen's Genetic Services Business Division also provides state-of-the-art genotyping services to the research community. With discovery activities and intellectual property focused on autism and oncology, IntegraGen's core strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

IntegraGen is listed on the Alternext market at NYSE Euronext Paris (ISIN code: FR0010908723; ticker Code: ALINT). For more information, visit [www.integragen.com](http://www.integragen.com).

## **CONTACTS**

### **INTEGRAGEN**

Bernard Courtieu  
Chairman and CEO  
[Contact@integragen.com](mailto:Contact@integragen.com)  
Tel.: +33 (0)1 60 91 09 00

Patrick Court  
Assistant CEO  
[Contact@integragen.com](mailto:Contact@integragen.com)  
Tel : +33 (0)1 60 91 09 09

### **LT VALUE**

#### **Investor Relations**

Nancy Levain / Maryline Jarnoux-Sorin  
[nancy.levain@ltvalue.com](mailto:nancy.levain@ltvalue.com) / [maryline.jarnoux-sorin@ltvalue.com](mailto:maryline.jarnoux-sorin@ltvalue.com)  
Tel : +33 (0)1 44 50 39 30 - +33 (0)6 72 28 91 44

#### **Press Relations**

Antoinette Darpy  
[antoinette.darpy@ltvalue.com](mailto:antoinette.darpy@ltvalue.com)  
Tel : +33 (0)6 72 95 07 92

## INTEGRAGEN SA

<b>INCOME STATEMENT In €</b>	<b>31-12-2010</b>	<b>31-12-2009</b>
Sales	3 208 031	2 813 085
Other Income	101 878	94 209
<b>Revenue</b>	<b>3 309 909</b>	<b>2 907 294</b>
Purchases of goods and external services	(3 993 497)	(3 724 101)
Indirect taxes	(63 401)	(96 945)
Wages and salaries	(1 839 456)	(1 660 669)
Operating depreciation / provision	(33 283)	(202 881)
Other operating expenses	(188 126)	(59 247)
<b>Operating expenses</b>	<b>(6 117 766)</b>	<b>(5 743 846)</b>
<b>Operating result</b>	<b>(2 807 857)</b>	<b>(2 836 551)</b>
Financial income	180 182	113 730
Financial expenses	(380 753)	(683 461)
<b>Financial result</b>	<b>(200 570)</b>	<b>(569 731)</b>
Exceptional income	33 179	93 012
Exceptional expenses	(537 710)	(19 459)
<b>Exceptional result</b>	<b>(504 531)</b>	<b>73 553</b>
Income tax (Research Tax Credit)	616 543	599 063
<b>Net profit or loss</b>	<b>(2 896 416)</b>	<b>(2 733 667)</b>

## INTEGRAGEN SA

<b>ASSETS</b> <b>In €</b>	<b>31-12-2010</b>	<b>31-12-2009</b>
Intangible fixed assets	262	
Tangible fixed assets	58 790	56 450
Financial fixed assets	377 906	46 204
<b>Total fixed assets</b>	<b>436 959</b>	<b>102 655</b>
Inventory and Work In Progress	92 935	365 619
Operating Receivables	789 300	1 055 796
Other Receivables	843 161	1 234 435
Cash	6 017 649	1 428 732
<b>Total current assets</b>	<b>7 743 047</b>	<b>4 084 584</b>
<b>Total assets</b>	<b>8 180 006</b>	<b>4 187 240</b>

<b>LIABILITIES</b> <b>In €</b>	<b>31-12-2010</b>	<b>31-12-2009</b>
Equity share capital	3 771 471	2 971 322
Share premium	30 800 355	24 851 253
Reserves and Retained earnings	(26 542 718)	(23 809 051)
Net income	(2 896 416)	(2 733 667)
<b>Equity</b>	<b>5 132 691</b>	<b>1 279 856</b>
<b>Other share capital</b>	<b>682 094</b>	<b>366 194</b>
<b>Provisions</b>	<b>40 720</b>	<b>8 917</b>
Financial debts	42 375	90 131
Trade payables	1 094 973	1 304 996
Other liabilities	1 187 149	1 137 142
<b>Total debts</b>	<b>2 324 499</b>	<b>2 532 271</b>
<b>Total liabilities</b>	<b>8 180 006</b>	<b>4 187 240</b>